👋 hey researchers,
Welcome back to the September edition of the Reptides Dispatch. There is a lot to get through in this one.
On August 5 Lilly reported Q2 results. Its tirzepatide franchise generated roughly $14.9 billion in three months. And it seems like they would like to keep that going, because seven days later the same company filed six federal lawsuits over a drug it does not sell, cannot fill a prescription for, and will not submit for approval until 2027.
The one, the only, retatrutide.
Lilly is clearly winning the open obesity market. So they pivoted and spent the rest of the month going after the version of retatrutide people can actually buy.
August did not look great for GLP-1 peptides, at least not the ones Eli Lilly holds IP on. Two large peptide YouTube channels went offline, three countries moved against research-use peptides, and on the 27th the compounding industry lost the appeal that was its last route back to legal mass-produced semaglutide and tirzepatide.
Retatrutide is the molecule in the filings, but the pressure did not stay on retatrutide. Research-use-only took hits as a category from state medical boards, regulators in Qatar, the Netherlands, and India, and much of the platform layer the market actually runs on. And the PCAC vote we led with last issue, where six peptides got favorable recommendations for the 503A list, has not moved an inch since.
So this issue runs the timeline, the court ruling that made all of it possible, who got hit, and where those six votes stand today.
- enforcement · six lawsuits and the platform squeeze
- boards · three states, three different answers
- compounding · the shortage door closed on the 27th
- follow-up · the six PCAC votes, six weeks later
- international · qatar, the netherlands, india
- trial · the VA tests GLP-1s for alcohol use disorder
put simply, Eli Lilly spent august trying to erase the only retatrutide anyone can buy.
Start with the earnings, because they explain the urgency. The oral GLP-1 is very real and beginning to print money. Foundayo's prescriber base went from 8,000 to 36,000 in a quarter. Under the Medicare bridge that opened July 1, roughly 80% of people getting treatment were still choosing the injectable. And excluding changes to rebate and discount estimates, US realized price fell about 9%.
Retatrutide is the opposite situation. The Phase 3 data package is complete across obesity, sleep apnea, and knee osteoarthritis pain, and management described the weight loss as approaching bariatric surgery levels. The BLA does not get filed until Q1 2027, and the company is still completing the CMC package.
Lilly is also in active litigation with FDA over whether retatrutide is classified as a biologic. If it is, it sits outside the ordinary 503A and 503B drug-compounding pathways entirely. Eli Lilly wants total control over retatrutide in the market, and they want it for as long as possible.
Ken Custer, who runs Lilly Cardiometabolic Health, said people are eagerly awaiting authentic reta, and that once it reaches market, people will "vote with their feet and embrace the really guaranteed product." Although their legal filings tend to paint a different story.
A licensed compounding pharmacy and a med spa are in the same filing wave as research-use-only vendors. Eli Lilly seems to be making a very clear point. Whether a seller called it a prescription or called it a reagent did not change whether Lilly sued.
Alongside the filings, Lilly publicly called on social media platforms, e-commerce sites, payment processors, credit card companies, and shipping carriers to cut sellers off. That last list is the part with no court in it. A payment processor does not need a verdict to drop an account.
They also went quiet on their own pipeline. Per Endpoints on August 27, and confirmed on Lilly's own pipeline page, Phase 1 projects are no longer disclosed. Whatever sits behind tirzepatide, retatrutide, and orforglipron stays hidden longer, from competitors and from everyone else.
For years, grey-market sellers had one reliable defense. Only FDA polices unapproved drugs. A drug company is not FDA, so a private competitor cannot simply enforce the FDCA itself. Judges accepted versions of that argument, and cases got dismissed.
Zyla Life Sciences v. Wells Pharma changed the map. Two companies sold the same anti-inflammatory, indomethacin. Zyla sold the FDA-approved version. Wells Pharma, a compounding pharmacy, made its own without approval and sold it in competition. Zyla sued. The trial court threw it out on exactly the reasoning above. The Fifth Circuit reversed.
The logic: six states at issue in Zyla have drug laws that mirror the federal approval requirement, and claims under those state-law rules were not automatically preempted just because they incorporated the same federal standard. That does not give drug companies a private right to enforce the FDCA. It does mean a defendant in the Fifth Circuit cannot end a parallel state-law case simply by saying only FDA can enforce federal drug law.
The sixth case is the med spa, in the Eastern District of California. That is the Ninth Circuit, where courts have taken a more restrictive view of private state-law claims tied to FDCA violations. It is the case in this batch most likely to test the circuit split directly.
One thing to hold onto: Zyla involved a drug with an approved version already on the market. Retatrutide does not have one. Whether Lilly's state-law theory carries cleanly against a molecule that has never been approved anywhere is still an open question in these cases.
Lone Star is the one worth reading. It carried every disclaimer you could ask for:
Lilly went after the site instead:
- the peptide calculator, and a separate retatrutide dosage calculator
- a reconstitution walkthrough using BAC water
- a titration schedule with each step held for weeks
- a 21+ age gate
the age gate is the sharp one.
Nobody checks ID before selling a reagent for cell culture work. It was added to look responsible and it ended up in a federal complaint as evidence the operator knew a person was going to inject the product. Same argument for the rest. A diagram showing which tick mark to draw to has no use in a beaker.
On damages, Lilly is arguing something unusual. Because no legal retatrutide exists, every person's first experience with the molecule is a grey-market vial. When something goes wrong, an underfilled vial, a bad dose, harsh sides, people blame the molecule rather than the seller. By launch, Lilly says it will be rehabilitating the reputation of a product it never sold. The other half is straight lost sales.
The complaint cites a Reddit user reporting that ten 20mg vials of retatrutide ran about half the cost of a single 7.5mg Mounjaro pen. Lilly put that in its own filing.
The filings also catalogue the codenames vendors used to sell retatrutide without typing retatrutide:
FDA decoded all of them in warning letters and named who was selling what. One vendor was cited for advertising triple the fat burning power. FDA is describing this as a new phase of enforcement:
August 17, the aftermath: the YouTube channels for Josh Holyfield and Trevor Bachmeyer went offline amid reports of platform enforcement. Both later reappeared. Worth being precise about who that is, because most of the coverage filed them under peptide influencers. Both operate their own research-use-only peptide brands. The channels were the top of the funnel for products they sell.
Neither operator was named in any of the six complaints, and there is no public evidence Lilly requested or caused either channel action. The timing still matters. Lilly had just publicly called on platforms to act, and platform enforcement can move without a court judgment.
For anyone buying rather than selling, that is the part that changes first. Court cases run for years. A channel, a server, a payment processor, or a shipping account can go away the week somebody files a report.
and it is not just Lilly clamping down on the peptide market. it is the medical boards too.
State boards are now telling providers directly that research-grade peptides do not go into patients. This targets clinics, med spas, and nurses. The lawsuits target sellers. Two separate campaigns that happen to be converging.
The part almost nobody quoted is the patient carve-out. The same statement says that when a patient independently acquires and self-administers these substances, the risk rests solely with the patient, while any involvement by a medical professional in recommending, supplying, prescribing, or administering them is the practice of medicine and is prohibited. Read plainly, the boards are regulating providers, not individuals.
Louisiana's carve-out protects the legal compounded pathway. It does nothing for the research-use market, but it is not all doom and gloom for compounded peptides.
All three of those states sit in the Fifth Circuit. In the same month, Louisiana shielded providers working through a licensed compounder, Mississippi closed the door on research-grade product entirely, and Texas hosted five lawsuits built on a Fifth Circuit ruling. Same circuit, three different answers.
a big change no one is talking about.
August 27, per Bloomberg Law: the Fifth Circuit upheld FDA's removal of both tirzepatide and semaglutide from the drug shortage list. The Outsourcing Facilities Association challenged both decisions. FDA won both.
Those shortage declarations were the legal basis for mass compounding of copycat Mounjaro, Zepbound, Ozempic, and Wegovy. With the removals upheld, the shortage-based route back to legal large-scale copies is closed. Compounding itself did not disappear: 503A patient-specific compounding still exists, and 503B facilities still exist for products that are not prohibited copies. What disappeared is the opening that allowed copies at scale.
Note which court that is. The same circuit that gave Lilly its opening in Zyla in April 2025 shut the compounders' appeal in August 2026.
Pharma is expanding the warfront beyond courtrooms too. Bloomberg Law reported on August 24 that Lilly and Novo are increasingly challenging compounded GLP-1 advertising through BBB National Programs' National Advertising Division, a private self-regulatory body. Ten cases in the past year. Novo has filed five alongside 130 federal lawsuits, Lilly at least five alongside dozens.
NAD cannot fine anyone, and participation is voluntary. What it can do is move in months instead of years, and refer a company to FDA, FTC, state attorneys general, and the platforms carrying the ads. In May it found Noom could not adequately substantiate its "A Smaller Dose. A Smarter Start." claim. Willow Health discontinued its compounded semaglutide safety and efficacy claims after a referral.
july's six favorable votes, six weeks of silence.
Issue 04 led with the Pharmacy Compounding Advisory Committee voting favorably on six peptides for the 503A Bulks List, over FDA staff who had recommended against all seven nominees. The first BPC-157 result drew applause inside FDA headquarters.
Since then, nothing on the record. No proposed rule, no Federal Register notice, no addition to the final list, and no word on whether FDA accepts, narrows, or rejects any of the six recommendations.
That pace is normal. PCAC advises. FDA decides. Getting a substance onto the final list takes a proposed rule, a comment period, and a final rule. Months to years is the standard, not the exception.
It reads differently sitting next to August. The one process that could make these six legally compoundable has not started, while enforcement moved across multiple jurisdictions in a single month. A favorable vote with no rule behind it protects a vendor, a clinic, or a pharmacy from none of it.
the research-use label does not travel.
Three regulators moved against research-use peptides in the same two weeks:
the VA is testing GLP-1s for alcohol use disorder.
The CRAVE trial has opened. Weekly semaglutide or placebo in veterans with moderate or severe alcohol use disorder:
It grew out of a March analysis of more than 600,000 veterans with type 2 diabetes that found lower risks of alcohol and several other substance use disorders in the GLP-1 group versus SGLT-2 inhibitors. A 2025 JAMA Psychiatry RCT had already shown low-dose semaglutide cutting drinks per drinking day and alcohol cravings versus placebo.
More than 400,000 veterans currently carry an AUD diagnosis. People on GLP-1s have been reporting reduced desire to drink for years, and the reward pathways involved overlap with the ones that quiet food noise. CRAVE is the much larger Phase 3 test of whether that signal holds in a population selected for the disorder rather than for weight.
reptides editorial · research reference, not medical advice. a complaint is an allegation. nothing in the six retatrutide cases has been decided.
the full research layer.
Membership unlocks every deep dive, the full research lab, supplier and outcome tools, stack grading, saved reconstitution context, unlimited COA checks, advanced journal tools, and unlimited Ask Reptides. It also keeps Reptides independent: no vendor money, peptide-vendor affiliate links, or paid grades.
$100 once. Lifetime access covers the same account on web, desktop, and iOS, with no subscription or renewal.
your peptide research desk, now pocket-sized.
With the Reptides app, you can scan a vial to pull up its grade, run reconstitution math without rebuilding the equation in Notes, and keep a private research journal that syncs across devices. The wiki and the journal stay free. So does tracking a stack, one COA check a day, your first vial scan, and ten Ask questions a month.
get reptides on the App Store →
James Lake · Chief Bro Officer & Co-Founder, Reptides · @reptidesco · @James9thlife